CLINICAL RESEARCH e-ISSN 1643-3750 © Med Sci Monit, 2017; 23: 5760-5766 DOI: 10.12659/MSM.904090
A Multicenter and Randomized Controlled Trial of Bicyclol in the Treatment of Statin-Induced Liver Injury
Received: 2017.02.28 Accepted: 2017.06.09 Published: 2017.12.04
Authors’ Contribution: Study Design A Data Collection B Analysis C Statistical Data Interpretation D Manuscript Preparation E Literature Search F Collection G Funds
ABE 1 BF 2 BD 3 CD 1 F 1 F 1 CD 1
CF 2
BCD 3
AE 1
Wu Naqiong Wang Liansheng Han Zhanying Guo Yuanlin Zhu Chenggang Gao Ying Dong Qian Liu Dongchen Zhou Yanjun Li Jianjun
1 Dyslipidemia and Cardiovascular Disease Center, Fuwai Hospital Chinese Academy of Medical Sciences, Beijing, P.R. China 2 Department of Cardiology, Jiangsu Province Hospital, Nanjing, Jiangsu, P.R. China 3 Department of Cardiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, P.R. China
Corresponding Author: Source of support:
Li Jianjun, e-mail:
[email protected] Departmental sources
Background: Material/Methods:
Results:
Conclusions:
The aim of this study was to evaluate the efficacy and safety of bicyclol treatment in statin-induced liver injury. The study included 168 patients with liver injury caused by statins. Patients were randomized into two fourweek treatment groups: bicyclol 25 mg three times daily or polyene phosphatidylcholine 456 mg three times daily as control. Serum biochemical indexes were compared before and after treatment. Significant differences in alanine transaminase (ALT) levels among the three measurements before and after treatment in the two groups at different time points were observed (p